(Q51468797)

English

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

scientific article published on 26 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

K Hermansen

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

M Kipnes

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

E Luo

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

D Fanurik

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

H Khatami

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

P Stein

6

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

Sitagliptin Study 035 Group

7

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

publication date

26 June 2007

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

733-745

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00744.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2007.00744.X

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17593236

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51468797&oldid=1236915596"